lanthanum carbonate · Takeda Pharms Usa · NDA 021468, 204734
Fosrenol
Earliest generic entry, as listed · earliest of 5 marketed strengths
1 Dec 2030
3 of 5 marketed strengths have no unexpired patent or exclusivity listed.
Blocked by patent: US 8980327, US 9023397.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8980327 | product | 1 Dec 2030 |
| US 9023397 | product | 1 Dec 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 6
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021468 · 001 · discontinued | tablet, chewable, oral | EQ 250MG BASE | open |
| 021468 · 002 · RLD | tablet, chewable, oral | EQ 500MG BASE | open |
| 021468 · 003 · RLD | tablet, chewable, oral | EQ 750MG BASE | open |
| 021468 · 004 · RLD | tablet, chewable, oral | EQ 1GM BASE | open |
| 204734 · 001 · RLD | powder, oral | EQ 750MG BASE | 1 Dec 2030 |
| 204734 · 002 · RLD | powder, oral | EQ 1GM BASE | 1 Dec 2030 |